1. PI3K/Akt/mTOR
  2. mTOR

WYE-125132 

Cat. No.: HY-10044 Purity: 98.39%
Handling Instructions

WYE-125132 (WYE-132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks).

For research use only. We do not sell to patients.
WYE-125132 Chemical Structure

WYE-125132 Chemical Structure

CAS No. : 1144068-46-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 165 In-stock
2 mg USD 108 In-stock
5 mg USD 144 In-stock
10 mg USD 252 In-stock
50 mg USD 864 In-stock
100 mg USD 1440 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

    WYE-125132 purchased from MCE. Usage Cited in: Patent. US 20160089377 A1.

    Western blot of cortical extracts from Cntnap2 mutant or wild-type mice treated with vehicle or various mTOR pathway inhibitors, showing staining for the presence of phosphorylated S6. Individual mice are tested, and are represented in the lanes as follows. Lane 1=Cntnap2+/− mouse 9-10 weeks old treated with vehicle as for AZD2014; Lane 2=Cntnap2+/− mouse 7.3 months old treated with Rapamycin; Lane 3=Cntnap2+/− mouse 6.3 months old treated with Torin 2; Lane 4=Cn

    WYE-125132 purchased from MCE. Usage Cited in: Patent. US 20160089377 A1.

    Treatment with WYE125132 rescues cellular, synaptic and molecular abnormalities in Cntnap2 mutants. Bar graphs (top) indicate that the dramatic increase in phosphorylation of S6 (Phospho-S6: S6) in the cortex of Cntnap2−/− and Cntnap2+/− mice is completely reversed with by treatment with WYE125132. In Bar graphs, each pair reflects untreated (left) and treated (right) values. Representative immunoblots are shown (bottom).
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    WYE-125132 (WYE-132) is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC50: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks).

    IC50 & Target

    IC50: 0.19±0.07 nM (mTOR), 1179 nM (PI3Kα), 2380 nM (PI3Kδ), 1250 nM (hSMG1)[1]

    In Vitro

    WYE-125132 (WYE-132) potently inhibits recombinant mTOR via an ATP-competitive mechanism. WYE-125132 is a potent antiproliferative agent against a panel of cancer cell lines with IC50 values generally in the nanomolar range. In the typical 3-day dose-response studies, WYE-125132 exhibits a more profound antiproliferative activity than CCI-779 in MDA361 and other cells, as shown by the sharper inhibition at doses up to 10 μM. Fluorescence-activated cell sorting (FACS) analysis of inhibitor-treated (1 μM, 24 hours) MDA468, PC3MM2, U87MG, A549, and HCT116 cells indicates that WYE-125132 elicits a more profound increase in G1-phase and a reduction in S-phase cells than CCI-779. The WYE-125132–induced cell death is evident at 10 and 30 nM (6.2% and 13%, respectively) and is dose dependent, reaching 47% at 1 μM and 59% at 3 μM[1].

    In Vivo

    A single i.v. administration of 50 mg/kg WYE-125132 (WYE-132) into tumor-bearing mice leads to suppression of P-S6K(T389) and P-AKT(S473) for at least 8 hours in PC3MM2, MDA361, HCT116, and HT29 tumors, whereas the steady-state level of P-AKT(T308) is not significantly reduced, indicating that the antitumor efficacy of WYE-125132 under such dosing regimens reflects the suppression of mTOR rather than PI3K. Oral administration of WYE-125132 causes dose-dependent tumor growth delay in the PI3K/mTOR- and HER2-hyperactive MDA361 tumors with significant antitumor activity at 5 mg/kg, which correlates with a suppression P-S6 and P-AKT(S473) but not P-AKT(T308). An optimal dose of 50 mg/kg WYE-125132 induces a substantial regression of large MDA361 tumors. WYE-125132 also causes a potent and substantial tumor growth delay in the PTEN-null U87MG glioma[1].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.9246 mL 9.6228 mL 19.2456 mL
    5 mM 0.3849 mL 1.9246 mL 3.8491 mL
    10 mM 0.1925 mL 0.9623 mL 1.9246 mL
    Please refer to the solubility information to select the appropriate solvent.
    Kinase Assay
    [1]

    mTOR enzyme assays via dissociation-enhanced lanthanide fluorescent immunoassay, ATP matrix assays, and mTOR immune-complex kinase assays are performed. Assays of PI3Ks are performed. hSMG1 and ATR are assayed using glutathione S-transferase-p53 as a substrate, detected via DELFIA using an anti-P-p53 (S15) antibody. Assays of a panel of 230 protein kinases are performed[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    WYE-125132 (WYE-132) is dissolved in DMSO as 20 mM stocks and diluted before assays[1].

    Cell lines of MDA-MB-361, MDA-MB-231, MDA-MB-468, BT549, LNCap, A549, H1975, H157, H460, U87MG, A498, 786-O, HCT116, MG63, Rat1, HEK293, HeLa and PC3MM2 are used. MDA361 cells are treated for 3 d with CCI-779 and WYE-125132 (0.1 nM, 1 nM, 10 nM,100 nM, 1000 nM 10μM and 100μM). Cell growth assays and IC50 determination are performed. For immunoblotting, cultured cells are treated as indicated. Total cell lysates are prepared using NuPAGE lithium dodecyl sulfate sample buffer and immunoblotted with various antibodies[1].
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    WYE-125132 (WYE-132) is formulated in 5% ethanol, 2% Tween 80, and 5% polyethylene glycol-400 (Mice)[1].

    Mice[1]
    For mTOR biomarker studies, various tumors (400 mm3) grown s.c. in female nude mice are dosed by a single i.v. or oral injection with vehicle or WYE-125132 formulated in 5% ethanol, 2% Tween 80, and 5% polyethylene glycol-400. Tumor lysates are prepared and immunoblotted. For efficacy studies, nude mice bearing U87MG, MDA361, H1975, A549, A498, or 786-O tumors are staged and randomized into treatment groups (n=10). Mice are dosed orally with vehicle or WYE-125132 following qd x5 cycle regimen (5 d on, 2 d off) for up to four cycles. Temsirolimus/CCI-779 is formulated as WYE-125132 and dosed i.v. once weekly. Bevacizumab is formulated in PBS and dosed i.p. via its clinical regimen (200 μg/mouse; once weekly). Tumor growth is monitored and analyzed.
    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    519.6

    Formula

    C₂₇H₃₃N₇O₄

    CAS No.

    1144068-46-1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 62 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    WYE-125132
    Cat. No.:
    HY-10044
    Quantity: